Attenuation of exercise conditioning by low dose beta-adrenergic receptor blockade
RC Marsh,
WR Hiatt,
HL Brammell,
and
LD Horwitz
Because it has been shown that high doses of propranolol (40 to 80 mg orally, four times daily) markedly attenuate cardiovascular response to exercise training in healthy subjects, the effects of lower doses of this nonselective beta-adrenergic receptor antagonist on the conditioning response were investigated. Twelve normal men underwent maximal treadmill testing before and after a 6 week intensive exercise program. After an initial test, six men were randomized in a paired fashion to receive low dose propranolol and the others received no drug. The average propranolol dose +/- standard error was 22 +/- 4 mg four times daily, and the average decrease in maximal heart rate due to propranolol was 32 +/- 4 beats/min. Both groups trained at comparable intensities. At the end of the training period, propranolol was stopped and testing was repeated so that the effect of beta-receptor blockade was no longer present but the training effects still persisted. Maximal oxygen consumption increased in control subjects from 47.5 +/- 1.1 to 51.4 +/- 0.4 ml/kg per min (p less than 0.05) but was unchanged in those receiving propranolol (47.2 +/- 1.9 versus 47.4 +/- 1.5). Exercise duration increased in both groups but the increment was greater in the control group (+2.4 versus +1.1 min, p less than 0.05). It is concluded that low level beta-receptor blockade attenuates cardiovascular conditioning in normal subjects in exercise training programs. High levels of sympathetic stimulation during training appear to be important, if not essential, to the conditioning process.
This article has been cited by other articles:
|
|
|
|
 
M. M. Robinson, J. C. Richards, M. S. Hickey, D. R. Moore, S. M. Phillips, C. Bell, and B. F. Miller
Acute {beta}-adrenergic stimulation does not alter mitochondrial protein synthesis or markers of mitochondrial biogenesis in adult men
Am J Physiol Regulatory Integrative Comp Physiol,
January 1, 2010;
298(1):
R25 - R33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fraga, F. G. Franco, F. Roveda, L. N.J. de Matos, A. M.F.W. Braga, M. U.P.B. Rondon, D. R. Rotta, P. C. Brum, A. C.P. Barretto, H. R. Middlekauff, et al.
Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol
Eur J Heart Fail,
June 1, 2007;
9(6-7):
630 - 636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Demopoulos, M. Yeh, M. Gentilucci, M. Testa, R. Bijou, S. D. Katz, D. Mancini, M. Jones, and T. H. LeJemtel
Nonselective -Adrenergic Blockade With Carvedilol Does Not Hinder the Benefits of Exercise Training in Patients With Congestive Heart Failure
Circulation,
April 1, 1997;
95(7):
1764 - 1767.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Packer, W. S. Colucci, J. D. Sackner-Bernstein, C.-s. Liang, D. A. Goldscher, I. Freeman, M. L. Kukin, V. Kinhal, J. E. Udelson, M. Klapholz, et al.
Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure: The PRECISE Trial
Circulation,
December 1, 1996;
94(11):
2793 - 2799.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. A. Ades, P. G.S. Gunther, C. P. Meacham, M. A. Handy, and M. M. LeWinter
Hypertension, Exercise, and Beta-Adrenergic Blockade
Ann Intern Med,
October 15, 1988;
109(8):
629 - 634.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. V. LEIER, N. D. BAKER, and P. A. WEBER
Cardiovascular Effects of Ophthalmic Timolol
Ann Intern Med,
February 1, 1986;
104(2):
197 - 199.
[Abstract]
[PDF]
|
|
|
|
